Skip to search formSkip to main contentSkip to account menu

HE 3235

Known as: Androstane Steroid HE3235, HE-3235, HE3235 
An orally bioavailable adrenal steroid analogue with potential antineoplastic activity. Androstane steroid HE3235 appears to bind the androgen… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
17α-Alkynyl 3α, 17β-androstanediol non-clinical and clinical pharmacology, pharmacokinetics and metabolism
Summary17α-ethynyl-5α-androstane-3α, 17β-diol (HE3235, Apoptone) is an orally bioavailable synthetic analogue of 3… 
2012
2012
Sequencing of Cabazitaxel in Metastatic Castrate-Resistant Prostate Cancer: A Case Report
Prostate cancer is a common cancer in men; for metastatic disease, it has a 5-year survival rate of 30%. No FDA-approved therapy… 
2011
2011
17α-Ethynyl-5α-androstane-3α, 17β-diol Treatment of MNU-Induced Mammary Cancer in Rats
N-methyl-N-nitrosourea (MNU) induces estrogen-dependent mammary tumors in female Lewis rats. We explored the antineoplastic… 
2010
2010
HE3235, a synthetic adrenal hormone disease-modifying agent, in castrate resistant prostate cancer (CRPC): Results of phase I/II clinical trial.
4674 Background: HE3235 (17α-ethynyl-5α-androstane-3α, 17s-diol), an androstanediol analog, showed activity in preclinical CRPC… 
2009
2009
HE3235 inhibits growth of castration-resistant prostate cancer.
Treatments for advanced prostate cancer (CaP) typically involve androgen deprivation therapy. However, most patients eventually… 
2009
2009
Inhibition of androstenediol-dependent LNCaP tumour growth by 17α-ethynyl-5α-androstane-3α, 17β-diol (HE3235)
Androst-5-ene-3β, 17β-diol (AED) is an adrenal hormone that has been reported to sustain prostate cancer growth after androgen… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)